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Bone marrow mesenchymal stem cells (BMSCs) and myeloid lineage cells originate from the bone marrow, and influence each 
other in vivo. To elucidate the mechanism that controls the interrelationship between these two cell types, the signaling path-
way of signal transducer and activator of transcription 3 (Stat3) was activated by overexpressing Stat3C in a newly established 
c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mouse model. In this system, Stat3C-Flag fusion protein was overexpressed in 
myeloid lineage cells after doxycycline treatment. Stat3C overexpression induced systematic elevation of macrophages and 
neutrophils in multiple organs. In the lung, tissue neoplastic pneumocyte proliferation was observed. After in vitro cultured 
hSP-B 1.5-kb lacZ BMSCs were injected into the bitransgenic mice, BMSCs were able to repopulate in multiple organs, 
self-renew in the bone marrow and spleen, and convert into alveolar type II epithelial cells. The bone marrow transplantation 
study indicated that increases of myeloid lineage cells and BMSC-AT II cell conversion were due to malfunction of myeloid 
progenitor cells as a result of Stat3C overexpression. The study supports the concept that activation of the Stat3 pathway in 
myeloid cells plays an important role in BMSC function, including homing, repopulating and converting into residential AT II 
epithelial cells in the lung. 
Stat3C, mesenchymal stem cells, lung epithelial cells, transgenic mice, tissue remodeling, myeloid-derived suppressive 
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The lung has the largest epithelial surface area of the body 
in order to facilitate air exchange. Alveolar type II (AT II) 
epithelial cells synthesize and secrete pulmonary surfactant 
that is critical to prevent alveoli from collapse during res-
piratory cycles [1,2]. AT II epithelial cells also participate 
in pulmonary inflammation and injury repair. In the lung, 
AT II epithelial cells are the local progenitor cells for the 
alveoli and undergo significant phenotypic changes to ter-
minally differentiate into AT I cells [3,4]. In response to 
injury, AT II epithelial cells proliferate to create more AT II 
epithelial cells and differentiate into AT I epithelial cells [5]. 
Since the lung is constantly exposed to a range of insults 
from the surrounding environment, maintenance of lung 
function requires both host defense and epithelial cell dam-
age repair. Given the importance of AT II epithelial cells in 
the lung, it is necessary to understand homeostasis of AT II 
epithelial cells under disease conditions.  
Bone marrow stem cells (BMSCs) have multiple poten-
tials to convert into residential cells in multiple organs. 
They can be used for regenerative medicine, tissue repair 
and gene therapy. Extensive studies demonstrated that 
BMSCs contribute to lung tissue repairing during damage in 
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various conditions [6]. However, the molecular pathway 
and the genetic network that control these processes are 
poorly understood. The lung depends on pulmonary surfac-
tant for the normal respiratory and host defense functions. 
We demonstrated that blockage of neutral lipid metabolism 
induced BMSC conversion into AT II epithelial cells as a 
result of pulmonary remodeling (emphysema and hypercel-
lularity) in lysosomal acid lipase (LAL) knock-out mice 
(lal/) [7]. In lal/ mice, BMSC-AT II cell conversion is 
highly associated with systemic inflammation, especially 
with infiltration of myeloid cells (e.g., myeloid-derived 
suppressive cells) into the lung. These studies suggest a 
tight connection between functions of myeloid cells and 
BMSCs that are controlled by neutral lipid derivative hor-
mones and downstream mediators. Importantly, correction 
of LAL expression in myeloid cells alone significantly im-
proved systemic inflammation and tissue remodeling [8,9]. 
Overexpression of LAL downstream genes in myeloid cells 
induced systemic inflammation and tumorigenesis in the 
lung [10–12]. Because both myeloid cells and BMSCs are 
originated from the bone marrow, we hypothesize that mal-
function of myeloid cells may affect the functional role of 
BMSCs in vivo. We aim at identifying pro-inflammatory 
intracellular signaling molecules in myeloid cells that con-
trol migration, repopulation and conversion of BMSCs to 
AT II epithelial cells in vivo. 
One such molecule is signal transducer and activator of 
transcription 3 (Stat3). Stat3 was originally identified as the 
acute phase response factor [13–15]. It is mainly activated 
by pro-inflammatory interleukin 6 (IL-6) family cytokines 
that share the common gp130 receptor subunit [16,17]. We 
demonstrated that persistent activation of the Stat3 pathway 
in lung epithelial cells directly caused pulmonary inflamma-
tion and bronchioalveolar adenocarcinoma [18,19], sup-
porting the concept that Stat3 is a pro-inflammatory mole-
cule and oncogene [20]. It has been reported that Stat3 was 
involved in myeloid differentiation [21]. Activation of Stat3 
by phosphorylation at Y705 was observed in myeloid cells 
of lal/ mice (Figure 1). To elucidate how activation of the 
Stat3 pathway in myeloid cells influences repopulation and 
AT II epithelial cell conversion of BMSCs, a previously 
established myeloid-specific doxycycline-inducible bi-
transgenic mouse model system [8] was used to specifically 
induce Stat3C (a constitutively active form of Stat3) over-
expression. In this system, the “activator” transgenic mouse 
line bears the reverse tetracycline-responsive transactivator 
(rtTA) fusion protein under the control of the 7.2 kb 5′-     
flanking regulatory sequence and the downstream intron 2 
of the c-fms gene [22] (designated as c-fms-rtTA mice). The 
rtTA expression is restricted to myeloid lineage cells in 
transgenic mice. In the second transgenic mouse line, the 
Stat3C cDNA is under the control of the tet operator DNA 
binding sequence that is linked to a minimal promoter (des-
ignated as (TetO)7-CMV-Stat3C mice) [18,23]. After cross-
breeding, expression of Stat3C is induced by addition of 
doxycycline in bitransgenic mice (designated as c-fms-     
rtTA/(TetO)7-CMV-Stat3C bitransgenic mice). We discov-
ered that activation of the Stat3 pathway in myeloid cells of 
c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice caused 
systemic increase of myeloid-derived suppressive cells 
(MDSCs) from the hematopoietic system (e.g., bone mar-
row and blood) to the immune system (e.g., spleen) to the 
tissue organs (e.g., lung). By using hSP-B 1.5-kb lacZ ad-
herent BMSCs, we demonstrated that Stat3C overexpres-
sion in myeloid cells facilitates migration and repopulation 
of BMSCs in the bone marrow and spleen of c-fms-rtTA/     
(TetO)7-CMV-Stat3C recipient bitransgenic mice. It also 
facilitates BMSC-AT II cell conversion at a 10% rate in 
doxycycline-treated recipient c-fms-rtTA/(TetO)7-CMV-    
Stat3C bitransgenic mice. The study supports the concept 
that activation of the Stat3 pathway in myeloid cells can 
facilitate BMSC residing in the recipient mouse bone mar-
row, migrating into the lung and converting into residential 
AT II epithelial cells.  
1  Materials and methods  
1.1  Animal care 
All scientific protocols involving the use of animals in this 
study have been approved by the Institution Animal Care 
and Usage Committee (IACUC) and follow guidelines es-
tablished by the Panel on Euthanasia of the American Vet-
erinary Medical Association. Protocols involving the use of 
recombinant DNA or biohazardous materials have been 
reviewed by the Biosafety Committee, and followed the 
guidelines established by the NIH. Animals were housed 
under IACUC-approved conditions in a secured animal fa-
cility. Animals were regularly screened for common patho-
gens (specific pathogen free). Experiments involving animal 
sacrifice utilize CO2 narcosis to minimize animal discom-
fort. 
1.2  Generation of doxycycline-controlled Stat3 trans-
genic mice 
The (TetO)7-CMV-Stat3C transgenic mouse line and the 
c-fms-rtTA transgenic mice were established as previously 
described [8,23]. C-fms-rtTA/(TetO)7-CMV-Stat3C bitrans-
genic mice were obtained by crossbreeding the c-fms-rtTA 
transgenic mice and (TetO)7-CMV- Stat3C transgenic mice. 
In general, animals were treated with doxycycline at 1 
month old age after genotyping. 
1.3  AT II cell and macrophage purification 
Alveolar type II epithelial cells and macrophages were puri-
fied as described previously [7]. 
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Figure 1  Activation of Stat3 in myeloid lineage cells in lal/ mice. Single cell suspensions were prepared from the bone marrow, blood (PBMC), spleen 
and lung of 3-month lal+/+ and lal/ mice for FACS analyses of relative phosphor-Stat3 cell populations (pStat3) in myeloid cells. Each experiment repre-
sents 3 independent (n=3) studies. lal+/+, wild-type mice (gray line); lal/, LAL knockout mice (black line); Shaded areas were isotype controls. M1 is a  
histogram marker excluding isotypic control (negative control). 
 
1.4  BMSCs isolation, culturing and marker defining 
The procedures for BMSC isolation and in vitro culturing 
were the same as previously described [7]. 
1.5  FACS analyses  
FACS analysis of CD11b, Gr-1, CD3 and B220 cells was 
the same as previously described [24,25]. FACS analysis of 
Stat3C-Flag fusion protein was analyzed by monoclonal 
ANTI-FLAG® M2-FITC antibody (F4049; Sigma, Saint 
Louis, MI). For intracellular phosphor-Stat3 analysis in 
lal/ mice, the assay was performed according to the pro-
tocols from Cell Signaling Technology (Danvers, MA). 
Briefly, after cell surface marker staining, cell suspensions 
from bone marrow, blood, spleen and lung of lal/ mice 
were fixed with 2% formaldehyde. Fixation samples were 
resuspended in methanol at a final 90% concentration. Fi-
nally, samples were washed and resuspended in 1× phos-
phate-buffered saline (PBS) containing 4% fetal bovine serum 
(FBS) at 106 cells in 100 μL. Cell suspensions were labeled 
with the primary anti-phospho-Stat3 antibody (Cell Signal-
ing Technology) for 30 min at room temperature, washed in 
PBS containing 4% FBS, and labeled using the secondary 
antibody. After washing, samples were analyzed by FACS.  
For BMSC marker analysis, in vitro cultured BMSCs 
(1×106–2×106 cells) at passages 0, 5, 7, 9, 11, 13, 15, 17, 19 
were harvested and blocked with FcR followed by incuba-
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tion with primary antibodies in FACS buffer. Anti-SSEA-1 
(Abcam, MA), anti-CD106 (VCAM-1; eBioscience), an-
ti-CD44 (IM7; eBiosciences), anti-Api6 (provided by Dr. 
Miyazaki, The University of Tokyo, Japan), anti-OCT-3/4 
(Octamer-3/4, N19; Santa Cruz Biotechnology, Santa Cruz, 
CA), anti-Nanog (Millipore, Temecula, CA), anti-BMP4 
(Bone morphogenic protein-4; Santa Cruz Biotechnology, 
CA), anti-SOX2 (SRY, or sex determining region Y-box 2; 
R&D Systems, Inc., Minneapolis, MN), anti-C-kit (CD117; 
eBiosciences), anti-Sca-1 (Ly6A/E, Stem Cell Antigen 1; 
eBiosciences), a biotin-Conjugated Mouse Lineage Panel 
(including biotin anti-mouse CD3, CD11b (Mac-1), 
CD45R/B220, TER-119, Ly-6G and Ly-6C; BD Bioscienc-
es, San Jose, CA) and AT II epithelial marker SP-C (FL-197; 
Santa Cruz Biotechnology, Santa Cruz, CA) were purchased 
for FACS analyses on a LSRII machine (BD Biosciences, 
San Jose, CA). Data was analyzed using the BD FACSta-
tionTM Software (BD Biosciences). 
For the BMSC-AT II cell conversion study, AT II epithe-
lial cells were labeled with PE anti-SP-C and FITC an-
ti‐‐galactosidase antibodies and analyzed as previously 
described [7]. Isotype controls IgG1, IgG2a and IgG2b were 
included in all experiments. Quadrants were assigned using 
isotype control. 
1.6   BMSC in vivo tracing and proliferation study 
The procedure was performed essentially the same as we 
described previously [7], except that c-fms-rtTA/(TetO)7-       
CMV-Stat3C bitransgenic mice were used. 
1.7    Real-time PCR 
For Real-time PCR analysis of the lacZ gene, total RNAs 
were purified from AT II epithelial cells using Qiagen RNA 
purification kit. A pair of sequence-specific oligonucleotide 
primers for the lacZ gene was used. Glyceraldehyde 
3-phosphate (GAPDH) primers were used as an endogenous 
control and normalizer for all samples. 
1.8   Double immunofluorescence staining 
The procedure for isolation and immunofluorescence stain-
ing of AT II epithelial cells was the same as previously de-
scribed [7]. For lung tissue section staining, tissue sections 
were rinsed in PBS-Tween 20 for 5 min, and incubated with 
normal mouse serum for 30 min to block non-specific bind-
ing of immunoglobulin. The sections were double stained 
with SP-C rabbit antibody (Santa Cruz Biotechnology, CA) 
and β-galactosidase mouse antibody (1:100 Sigma, St Louis, 
MO, USA). A Cy2-conjugated donkey anti-rabbit IgG and a 
Cy3-conjugated donkey anti-mouse IgG (Jackson Immu-
noResearch, West Grove, PA, USA) were used as the sec-
ondary antibodies.  
1.9   Immunoelectron microscopy 
For post-embedding electron microscopy, lung tissues were 
fixed with 4% paraformaldehyde in 0.1 mol L1 phosphate 
buffer, dehydrated through a graded series of ethyl alcohols 
and embedded in Unicryl (Electron Microscopy Sciences, 
Hatfield, PA). Thin sections (70–90 nm) were mounted on 
Formvar/carbon coated nickel grids. The grids were placed 
into a blocking buffer for 60 min and then into the primary 
antibody overnight at 4°C. The grids were then rinsed with 
phosphate buffered saline (PBS) and floated on drops of the 
appropriate secondary antibody attached with 10 nm gold 
particles (AURION, Hatfield, PA) for 2 h at room tempera-
ture. After rinsing with PBS the grids were placed in 2.5% 
glutaraldehyde in 0.1 mol L1 phosphate buffer for 15 min. 
After rinses with PBS and distilled water, the grids were 
allowed to dry and then stained for contrast with uranyl ac-
etate. The samples were viewed with a Tecnai Bio Twin 
transmission electron microscope (FEI, Hillsboro, OR) and 
images taken with a CCD camera (Advanced Microscopy 
Techniques, Danvers, MA). The experiment was performed 
by Electron Microscopy Core Facility at Indiana University 
School of Medicine. 
1.10  Bone marrow transplantation 
The procedure for bone marrow transplantation experiment 
was similar to that previously described [26]. Briefly, re-
cipient wild type mice (WT, CD45.2+) at 3-week old were 
lethally irradiated with 1000 rad of γ-irradiation and rested 
1 d prior to receiving cells. Bone marrow cells were pre-
pared from femurs and tibia of 810-week old donor wild 
type or c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice 
(CD45.1+). Reciprocal recipient mice (CD45.2+) were in-
jected with 2.5×106–5×106 donor bone marrow cells in 500 
L 1× PBS via tail vein. The chimeric mice either were 
treated or untreated with doxycycline for three months. A 
group of these chimeric mice were used for inflammatory 
cell analyses. Another group of these chimeric mice were 
used for the BMSC injection study. Cultured adherent 
hSP-B 1.5-kb lacZ BMSCs after 9 passages were harvested 
and resuspended in 1× PBS. Each recipient chimeric mouse 
was infused with adherent hSP-B 1.5-kb lacZ BMSCs 
through tail vein as described above. After 6 weeks of 
BMSCs injection, the bone marrow, blood, spleen and lungs 
from various groups were harvested for BMSC-AT II cell 
conversion analysis. 
1.11  Statistical analysis 
The data shown were mean values of at least three inde-
pendent experiments and expressed as mean±SD. A paired 
Student’s t test or ANOVA was used to evaluate the signif-
icance of the differences. Statistical significance was set at a 
level of P<0.05. 
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2  Results 
2.1  Activation of Stat3 in myeloid cells during LAL 
deficiency 
During LAL deficiency, systemic infiltration of mye-
loid-lineage macrophages and neutrophils in multiple or-
gans is a major manifestation of pathogenesis [8,27–29]. 
Inflammation triggered BMSC conversion into AT II epi-
thelial cells in lal/ mice [7]. However, the cellular and 
molecular mechanism for this event is not clear. Because 
both myeloid lineage cells and BMSCs are originated from 
the bone marrow, it is possible that activation of myeloid 
lineage cells affects the BMSC behavior. To identify which 
inflammatory signaling molecules are activated in mye-
loid-lineage cells during LAL deficiency, important intra-
cellular signaling molecules were tested by FACS. Interest-
ingly, activation of Stat3 phosphorylation at Y705 was ob-
served at various developmental stages of myeloid-lineage 
cells in multiple organs, including the bone marrow, blood, 
spleen and lung (Figure 1). Our results demonstrated that 
the percentage numbers of phosphor-Stat3 positive CD11b+ 
macrophages and GR-1+ neutrophils in lal/ mice were 
highly increased compared with those of lal+/+ mice. 
Therefore, it is possible that Stat3 activation in myeloid 
lineage cells facilitate BMSCs migration, homing and con-
verting into AT II epithelial cells.  
2.2  Generation of c-fms-rtTA/(TetO)7-CMV-Stat3 bi-
transgenic mice 
To directly show that activation of the Stat3 pathway in 
myeloid-lineage cells can increase inflammation and 
BMSC-AT II cell conversion, a doxycycline-controlled bi-
transgenic mouse model was generated to specifically direct 
Stat3 expression in myeloid cells. Figure 2A illustrates my-
eloid lineage-specific expression of the c-fms-rtTA/(TetO)7-     
CMV-Stat3C bitransgenic gene. In this system, a previously 
established c-fms-rtTA transgenic mouse line [8] was 
crossbred with a previously generated (TetO)7-CMV-Stat3C 
transgenic mouse line [23]. In order to assess the expression 
pattern of Stat3C in c-fms-rtTA/(TetO)7-CMV-Stat3C bi-
transgenic mice, a Flag sequence was added at the C termi-
nus of the Stat3C cDNA to distinguish exogenous Stat3C-     
Flag fusion protein from endogenous Stat3 protein. Bi-
transgenic mice were treated with or without doxycycline 
for 5 months and were sacrificed for FACS analysis. Sin-
gle-cell suspensions from the bone marrow, blood, spleen 
and lung were double stained with Flag antibody and anti-
bodies specific for macrophages (CD11b), dendritic cells 
(DCs, CD11c), neutrophils (GR-1), or T cells (CD3). Mye-
loid-lineage CD11b+ macrophages, Gr-1+ neutraphils and 
CD11c+ DCs all showed Stat3C-Flag overexpression in 
tested organs of doxycycline-treated bitransgenic mice. As a 
negative control, there was no Stat3C-Flag induction in 
CD3+ T lymphocytes, SP-C+ AT II epithelial cells and 
CCSP+ Clara cells regardless of doxycycline treatment in 
bitransgenic mice (Figure 2B and C). These results demon-
strated that Stat3C-Flag fusion protein overexpression in 
c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice was 
myeloid lineage-specific. No Stat3C-Flag fusion protein 
was detected in myeloid lineage cells in above mentioned 
organs of wild type mice regardless of doxycycline treat-
ment (data not shown), suggesting that induction of 
Stat3C-Flag fusion protein was not caused by doxycycline 
alone. 
2.3  Overexpression of Stat3C caused systemic inflam-
mation and lung tissue neoplastic proliferation 
C-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice were 
treated with or without doxycycline for 5 months. The cells 
from the bone marrow, blood, spleen and lung were isolated 
and stained with fluorochrome-conjugated antibodies spe-
cific for macrophages, DC, neutrophils, B cells or T cells 
for FACS analysis. Compared with those from doxycy-
cline-untreated mice, the percentage of CD11b+ macro-
phages was increased from 6.85% to 10.94% in the blood 
(PBMC), 1.83% to 3.09% in the spleen and 13.18% to 
17.43% in the lung of doxycycline-treated bitransgenic mice. 
The percentage of GR-1+ neutrophils was increased from 
4.41% to 7.33% in the blood (PBMC), 0.68% to 4.99% in 
the spleen and remained unchanged in the lung of doxycy-
cline-treated bitransgenic mice. Interestingly, the percentage 
of CD11b+ GR-1+ myeloid cells was increased from 6.56% 
to 17.14% in the blood, 1.08% to 4.30% in the spleen and 
3.63% to 14.73% in the lung of doxycycline-treated bi-
transgenic mice (Figure 3A). The absolute numbers of these 
cells were also systematically increased (Table 1). There-
fore, Stat3C overexpression in myeloid lineage cells can 
increase systemic myeloid cells (especially CD11b+ GR-1+ 
cells) in various organs of bitransgenic mice. In the lung, 
pathogenesis of doxycycline-treated or untreated c-fms-      
rtTA/(TetO)7-CMV-Stat3C bitransgenic mice was further 
analyzed by histology. Lung inflammation and neoplastic 
pneumocyte proliferation were observed in 10–15 month 
doxycycline-treated bitransgenic mice (Figure 3B). In con-
trast to myeloid cells, changes of T and B lymphocytes were 
not observed in bitransgenic mice regardless of doxycycline 
treatment (Table 1). 
2.4  BMSC markers 
To assess BMSC-AT II cell conversion, a previously pub-
lished method was used to obtain BMSCs that were en-
riched from the whole bone marrow via plastic adherent of 
fibroblastoid cell fraction in specific culture medium [7]. 
Although this fractionation method was used for isolation of 
BMSCs, little is known about markers that define 
self-renewal BMSCs. In our cultured condition, BMSCs  
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Figure 2  Generation of doxycycline-controlled c-fms-rtTA/(TetO)7-CMV-Stat3C double-transgenic mice. A, Construct maps for c-fms-rtTA single trans-
genic mice, (TetO)7-CMV-Stat3C single transgenic mice and double transgenic progeny. B, Myeloid specific expression of Stat3C-Flag fusion protein in 
c-fms-rtTA/(TetO)7-CMV-Stat3C double-transgenic mice. Cells from the bone marrow, blood (PBMC) and spleen of 3-month doxycycline-treated (+DOX, 
black line) and untreated (DOX, gray line) bitransgenic mice were stained with anti-Flag antibody in combination with cell-surface markers CD11b, CD11c, 
GR-1 and CD3. In gated CD11b+, CD11c+, GR-1+ and CD3+ cells, Flag+ cells were analyzed by FACS in histograms. Isotype controls were shown as the 
shaded areas. C, The above study was repeated in the lung, except that cell-specific anti-SP-C (AT II epithelial cell marker) and -CCSP (Clara cell marker)  
antibodies were also used for analysis. M1 is a histogram marker excluding isotypic control (negative control). 
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Figure 3  Systemic increases of myeloid cells in c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice. A, Single cell suspensions were prepared from the 
bone marrow, blood (PBMC), spleen and lung of 3-month doxycycline-treated and untreated bitransgenic mice for FACS analyses. Distribution of CD11b+ 
macrophage and GR-1+ cells was presented in dot plots. Each experiment represents 3 independent (n=3) studies. –DOX, doxycycline-untreated bitransgenic 
mice; +DOX, doxycycline-treated bitransgenic mice. B, C-fms-rtTA/(TetO)7-CMV-Stat3 bitransgenic mice were treated or untreated with doxcycline for  
10–15 months. Lungs were inflated, sectioned and analyzed by H&E staining. 
Table 1  The absolute numbers of inflammatory cells in c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic micea) 
Cell types 


























































a) *, Significant increase, P<0.05. 
 
were mouse hematopoietic lineage panel negative (includ-
ing biotin-conjugated anti-mouse CD3ε, CD11b (Mac-1), 
CD45R/B220, TER-119, Ly-6G and Ly-6C) (data not 
shown). From 0 to 19 passages, BMSCs expressed relative-
ly high levels of Scal-1, SSEA-1, CD44, CD106 and apop-
tosis inhibitor 6 (Api6/AIM/Spα) under the cultured condi-
tion (Table 2). CD106, CD44 and SSEA-1 were previously 
defined markers for BMSCs [30–32]. Expression of Api6 
was identified for the first time in cultured BMSCs. By con-
trast, embryonic stem cell markers, such as OCT-4, BMP4 
and SOX2, and Nanog, were expressed at relatively low 
levels under the same cultured condition (Table 2), even 
though Nanog and Sox2 showed increased expression in 
BMSCs at later culturing passages (11–19). This suggests 
that BMSCs and embryonic stem cells have different char-
acteristics of marker expression, implicating differential 
function properties in vivo. In addition, cultured BMSCs did 
not express AT II epithelial marker SP-C throughout culture  
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Table 2  Expression of markers in in vitro cultured BMSCsa) 
Passages 0th (%) 5th (%) 7th (%) 9th (%) 11th(%) 13th (%) 15th (%) 17th (%) 19th (%) 
BMSC marker          
Sca-1 2.14 44.92 56.93 65.73 72.12 78.66 77.91 78.61 81.94 
SSEA-1 6.36 23.47 24.44 26.23 16.3 10.7 5.42 4.31 3.27 
Api6 2.16 8.84 11.97 43.78 14.6 20.31 32.78 33.17 29.89 
CD44 93.29 82.65 70.97 79.56 94.76 83.32 99.42 89.02 98.96 
CD106 6.15 81.55 80.1 83.21 57.61 50.71 57.69 59.61 49.25 
Embryonic stem cell marker          
OCT-3/4 1.89 1.07 1.04 1.2 1.47 1.7 1.39 3.17 4.29 
Nanog 0.78 1.97 3.61 1.8 5.23 8.08 12.42 12.9 19.2 
BMP4 0.34 0.86 1.29 1.41 1.94 1.23 3.74 1.92 3.23 
SOX2 6.10 1.04 1.35 1.54 4.68 5.28 10.06 9.72 8.03 
Type II epithelial marker          
SP-C 0.71 1.02 1.6 0.51 0.22 0.14 0.09 0.04 0.03 
a) Numbers represent percentage (%) of positive cells that express markers. BMSC, bone marrow stem cells; SSEA-1, stage-specific embryonic antigen-1; 
Api6, apoptosis inhibitor 6; OCT-3/4, octamer-3/4; BMP4, bone morphogenic protein-4; SOX2, sex determining region Y-Box 2; SP-C, surfactant protein C.  
 
 
passages. In the subsequent studies, BMSCs with 9–13 pas-
sages were routinely used for injection studies. 
2.5  Repopulation of donor BMSCs in c-fms-rtTA/ 
(TetO)7-CMV-Stat3C bitransgenic mice 
The experimental design for the bone marrow transplanta-
tion study involving c-fms-rtTA/(TetO)7-CMV-Stat3C bi-
transgenic mice and hSP-B 1.5-kb lacZ transgenic mice is 
illustrated in Figure 4A. First, organ repopulation and 
self-renew of injected adherent BMSCs in c-fms-rtTA/      
(TetO)7-CMV-Stat3C bitransgenic mice was assessed by 
carboxyfluoresein diacetate succinimidyl ester (CFSE) in 
cell tracing experiment. After enrichment by 9 passages in 
in vitro culturing, adherent BMSCs from hSP-B 1.5-kb lacZ 
transgenic mice were further purified by CD11b, CD34 and 
CD45 magnetic beads to remove macrophages and endothe-
lial cells. Purified BMSCs were labeled by CFSE and tail 
vein injected into doxycycline-treated or untreated c-fms-      
rtTA/(TetO)7-CMV-Stat3C bitransgenic mice. Two weeks 
later, single-cell suspensions were prepared from the bone 
marrow, spleen and lung of recipient mice. As demonstrated 
in Figure 4B, CFSE-labeled cells were readily detected in 
these organs of doxycycline-treated bitransgenic mice, but 
not in untreated bitransgenic mice (data not shown). This 
indicates that migration and homing of injected adherent 
BMSCs in recipient bitransgenic mice is associated with 
inflammation caused by Stat3 overexpression in myeloid 
lineage cells. Enriched BMSCs were able to proliferate as 
demonstrated in the cultured condition by a cell replication 
(proliferation) study, in which divided daughter cells (rep-
resented by different peaks) were separated by CFSE label-
ing (Figure 4C). After injection, adherent BMSCs were able 
to replicate in the bone marrow and spleen of doxycy-
cline-treated c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic 
mice by CFSE labeling (Figure 4D). No cell division of 
CFSE-labeled adherent BMSCs was observed in doxycy-
cline-untreated recipient c-fms-rtTA/(TetO)7-CMV-Stat3C 
bitransgenic mice (Figure S1). Therefore, donor adherent 
BMSCs were able to self-renew primarily in the bone mar-
row and spleen of doxycycline-treated c-fms-rtTA/(TetO)7-    
CMV-Stat3C bitransgenic mice.  
2.6  Conversion of hSP-B lacZ 1.5-kb BMSCs into AT II 
epithelial cells in c-fms-rtTA/(TetO)7-CMV-Stat3C bi-
transgenic mice 
To test if hSP-B 1.5-kb lacZ adherent BMSCs were able to 
convert into AT II epithelial cells in the lung of c-fms-      
rtTA/(TetO)7-CMV-Stat3C bitransgenic mice under the 
inflammatory condition, cultured (9 passages) and purified 
hSP-B 1.5-kb lacZ adherent BMSCs were injected into 
doxycycline-treated and untreated c-fms-rtTA/(TetO)7-        
CMV-Stat3C bitransgenic recipient mice. Six weeks after 
injection, AT II epithelial cells were isolated from recipient 
mice and stained with rabbit anti-proSP-C antibody and 
mouse -galactosidase antibody for flow cytometry (Figure 
5A). Approximate 8%–9% of proSP-C-positive cells 
showed -galactosidase co-staining in doxycycline-treated 
bitransgenic mice (Figure 5B). This observation was con-
firmed by double immunofluorescence staining at a conver-
sion rate of 10% in doxycycline-treated mice, but not in 
untreated mice (Figure 5C). No co-staining was observed in 
the doxycycline-untreated bitransgenic lung. To prove that 
these converted cells were in indeed located within the al-
veolar epithelium of the alveolar walls, double immunoflu-
orescence staining was performed on tissue sections (Figure 
5D). SP-C and -galactosidase signals were overlapped in 
some AT II epithelial cells located in the corner of the alve-
olar walls. In a systematical study, hSP-B 1.5-kb lacZ ad-
herent BMSCs cultured in vitro at various passage time 
points were injected into c-fms-rtTA/(TetO)7-CMV-Stat3C  
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Figure 4  Repopulation of hSP-B 1.5-kb lacZ adherent BMSCs in c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice by CFSE analysis. A, Schematic 
illustration of BMSC transplantation experiment. B, CFSE-labeled hsp-B 1.5-kb lacZ adherent BMSCs after 9 passages were injected into doxycy-
cline-treated c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice. After 2 weeks, distribution of donor BMSCs was detected by flow cytometry in various 
organs of the recipient c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice. Non-CFSE-labeled hsp-B 1.5-kb lacZ adherent BMSCs were used as control. C, 
Cell division of CFSE-labeled hSP-B 1.5-kb lacZ adherent BMSCs (+CFSE) was detected in the cultured condition after 5 passages, but not in 0 passage. D, 
Cell division of CFSE-labeled hSP-B 1.5-kb lacZ adherent BMSCs (+CFSE) was detected in the bone marrow and spleen of recipient doxycycline-treated 
c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice. Cell cycles of CFSE-labeled adherent BMSCs are indicated by arrows (n=3). M1 is a histogram marker 
excluding isotypic controls (negative controls). No BMSCs proliferation was observed in doxycycline-untreated recipient c-fms-rtTA/(TetO)7-CMV-Stat3C  
bitransgenic mice (Figure S1). 
 
bitransgenic mice to assess the ability of BMSC conversion 
into AT II epithelial cells. After 11 and 13 passages, hSP-B 
1.5-kb lacZ adherent BMSCs were still able to convert into 
AT II epithelial cells in doxycycline-treated c-fms-rtTA/     
(TetO)7-CMV-Stat3C bitransgenic mice using the same 
methods as outlined above. However, after 19 passages in 
vitro, hSP-B 1.5-kb lacZ adherent BMSCs failed to convert 
into AT II epithelial cells in c-fms-rtTA/(TetO)7-CMV-    
Stat3C bitransgenic mice regardless of doxycycline treat-
ment (data not shown). 
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Figure 5  Conversion of hSP-B 1.5 kb lacZ adherent BMSCs into AT II 
epithelial cells in recipient c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic 
mice. CD34- and CD45-negatively selected 9th passaged hSP-B 1.5-kb 
lacZ BMSCs were injected into c-fms-rtTA/(TetO)7-CMV-Stat3C bitrans-
genic mice with (+Dox) or without (Dox) doxycycline treatment. AT II 
epithelial cells were isolated from recipient mice for protein labeling and 
mRNA analyses. A, A representative of FACS analysis by anti-SP-C and 
-galactosidase antibodies. B, The percentage numbers of proSP-C/- 
galactosidase double positive cells from 4 independent FACS studies (n=4).  
*, P<0.01. C, Colocalization of proSP-C and -galactosidase double posi-
tive cells by immunofluorescence staining in isolated AT II epithelial cells. 
No colocalization was observed in doxycycline-untreated mice. Blue, DAPI 
staining of cell nuclei; green, pro-SP-C staining; red, -galactosidase stain-
ing; orange, double positive staining. D, Colocalization of proSP-C and 
-galactosidase double positive cells by immunofluorescence staining on 
lung tissue sections. Double positive cells are pointed out by arrows (or-
ange). No colocalization was observed in doxycycline-untreated mice. 
Green, pro-SP-C staining; red, -galactosidase staining. DAPI staining 
represents nuclei in the lung. E, Expression of lacZ mRNA in AT II epithe-
lial cells of bitransgenic mice (n=3). Wild type mice were used as  
negative control. 
Increased expression of -galactosidase was partially due 
to transcriptional up-regulation since the Real-Time PCR 
analysis showed increased mRNA expression in AT II epi-
thelial cells that were isolated from the lungs of recipient 
c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice (Figure 
5E). It is notable that there was a low level expression of 
lacZ mRNA in doxycycline-untreated mice, indicating a 
minor leakage in the system. This was also observed in Flag 
expression (PBMC; Figure 2). As a control, no -galac-      
tosidase mRNA expression was detected in wild type recip-
ient mice regardless of doxycycline treatment after injection 
of hSP-B 1.5-kb lacZ adherent BMSCs (Figure 5E).  
2.7  Bone marrow transplantation 
Although the above studies demonstrated that myeloid 
Stat3C-induced inflammation caused BMSCs-AT II cell 
conversion, they do not address a question whether these 
phenomenon is due to malfunction of myeloid lineage pro-
genitor cells, or due to the microenvironment change that 
affects progenitor cell development as a result of Stat3C 
overexpression in recipient mice. To address this issue, 
bone marrow cells from wild-type or c-fms-rtTA/(TetO)7-     
CMV-Stat3C bitransgenic mice (both CD45.1+) were trans-
planted into reciprocal recipients (CD45.2+) that were le-
thally irradiated to generate bone marrow chimeric mice. 
After three months, recipient mice were infused with in 
vitro cultured (9 passages) and purified hSP-B 1.5-kb lacZ 
adherent BMSCs through tail vein of doxycycline-treated or 
untreated recipient mice. After 6 weeks of BMSCs injection, 
the bone marrow, blood, spleen and lung were harvested 
from various groups for analysis. Recipient cells were ex-
cluded by gating on CD45.1+ cells that were derived from 
the donor mice. Four experimental bone marrow transplan-
tation (BMT) groups were designed including doxycy-
cline-untreated (DOX, c-fms/Stat3C→WT; DOX WT→
WT) or treated (+DOX, c-fms/Stat3C→WT; +DOX, WT→
WT) samples. First, myeloid lineage cells were analyzed 
(Figure 6A and B). The percentage of CD11b+ GR-1+ cells 
in the bone marrow (65.30%–76.82%) and lung (4.99%– 
15.43%) of the doxycycline-treated c-fms/Stat3C→WT 
BMT group was increased compared with those of the 
doxycycline-untreated c-fms/Stat3C→WT BMT group. The 
percentage of CD11b+ macrophages in the lung of the same 
group was increased from 14.70% to 24.52% and remained 
relatively unchanged in the bone marrow. The percentage of 
GR-1+ neutrophils in the lung of the same group was mod-
estly increased from 1.53% to 2.16% and remained rela-
tively unchanged in the bone marrow. In the control WT→
WT BMT group, CD11b+GR-1+, CD11b+ and GR-1+ cells in 
the doxycycline-treated group were not significantly differ-
ent from those in the doxycycline-untreated group (data not 
shown). In association with these observations, proSP-C 
and -galactosidase double positive AT II epithelial cells 
were increased to 9.8% by flow cytometry in the doxycy-
cline-treated c-fms/Stat3C→WT BMT group, but not in 
other groups (Figure 6C). Therefore, Stat3C-induced au-
tonomous of myeloid progenitor cells was the cause of 
BMSC-AT II cell conversion in c-fms-rtTA/(TetO)7-     
CMV-Stat3C bitransgenic mice. 
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To assess contribution made by the microenvironmental 
change in c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic 
mice, additional BMT groups were designed including 
doxycycline-treated or untreated WT→c-fms/Stat3C sam-
ples. As demonstrated in Figure 6A and B, no distinct 
changes of CD11b+GR-1+, CD11b+ and GR-1+ cells were 
observed in reciprocal transplanted mice. As a consequence, 
minimal BMSC-AT II cell conversion was observed (Figure 
6C). This result excluded the animal microenvironment as a 
cause to alter development of myeloid lineage progenitor 
cells and BMSC-AT II cell conversion. 
3  Discussion 
As we reported previously, Stat3 is a pro-inflammatory and 
oncogenic molecule. Over-activation of the Stat3 pathway 
mobilizes inflammatory cells to influx into the lung [18]. In 
this report, FACS analysis showed that Stat3 was activated 
in highly proliferative CD11b+ and GR-1+ cells in multiple 
organs of lal mice (Figure 1). It is possible that Stat3 ac-
tivation in myeloid cells mediates inflammation and BMSC 
conversion to AT II epithelial cells as observed in lal/ 
mice [7]. To prove this assumption, a myeloid-specific 
doxycycline-inducible c-fms-rtTA/(TetO)7-CMV-Stat3C bi-        
transgenic model system was established. FACS analysis 
with Flag antibody and cell specific antibodies showed my-
eloid cell-specific expression of Stat3C-Flag fusion protein 
in the bone marrow, blood, spleen and lung (Figure 2B). 
This is in agreement with our previous findings [8,11,12,33]. 
As a consequence, Stat3C over-expression in myeloid cells 
caused systemic increase of macrophages and neutraphils in 
bitransgenic mice. Importantly, the number of CD11b+GR-1+ 
positive MDSCs was significantly increased (Figure 3A). 
MDSCs have great potential to facilitate the processes of 
neoplastic tissue remodeling [3436]. Indeed, hyperplasia 
was observed in doxycycline-treated c-fms-rtTA/(TetO)7-     
CMV-Stat3C bitransgenic lungs (Figure 3B). 
In association with inflammation, BMSCs were analyzed 
to see if activation of the Stat3 pathway induces BMSC mi-
gration, repopulation and conversion into AT II epithelial 
cells in this animal model. To have a better understanding 
of BMSCs in our in vitro cultured condition, multiple 
markers were analyzed to define BMSC at multi-passage 
points. BMSCs cultured in our condition were low on ex-
pression of embryonic stem cell markers (OCT-4, BMP4, 
SOX2, and Nanog), and high on expression of Scal-1, 
SSEA-1, CD44 and CD106 markers. Sca-1 expression cor-
relates with the ability of murine BM stromal cells to sup-
port proliferation of BM cells [37]. SSEA-1 defined mesen-
chymal compartment has a high capacity to differentiate to 
astrocyte-, endothelial- and hepatocyte-like cells in vitro [32]. 
 
 
(to be continued on the next page) 




Figure 6  Inflammation and BMSC analyses in chimeric mice. Bone marrow cells from wild-type or c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice 
(CD45.1+) were transplanted into reciprocal mice (CD45.2+) that were lethally irradiated. Chimeric mice were treated with or without doxycycline. A, A 
representative analysis of CD11b+ and GR-1+ cells in the bone marrow and lung of chimeric mice by FACS. B, The percentage numbers of CD11b+ GR-1+ 
and CD11b+ GR-1 in the bone marrow and lung were analyzed in three independent studies (n=3–4). *, P<0.05; **, P<0.01. C, Two months after bone 
marrow transplantation and doxycycline treatment, cultured adherent 9th passage BMSCs were injected into chimeric mice. Six weeks later, AT II epithelial 
cells were isolated from recipient mice for FACS analysis by anti-SP-C and -galactosidase antibodies. A representative analysis and the percentage of  
proSP-C/-galactosidase double positive cells from 4 independent FACS (n=3–4) are demonstrated. **, P<0.01. 
CD44 and CD106 are adherent molecules. Modification of 
the glycans on CD44 increases the efficiency of BMSCs de-
livery and homing to the bone marrow [31]. CD106 expres-
sion has been linked to the hematopoietic supportive capacity 
of immortalized murine BM stromal cell lines [38,39]. In our 
analysis, expression of Api6 was also high in cultured 
BMSCs. Api6 is a secreted protein and belongs to the mac-
rophage scavenger receptor cysteine-rich domain superfam-
ily (SRCR-SF) [40,41]. Although Api6 was originally iden-
tified from macrophages, its expression was also identified 
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in AT II epithelial cells of lal/ mice [29]. Over-expression 
of this molecule in myeloid cells and lung AT II epithelial 
cells using the doxycycline-inducible systems stimulated 
proliferation and influx of macrophages, neutrophils and 
MDSCs in vivo, which resulted in lung adenocarcinoma 
[33,42]. Since expression of these markers were varied in 
different passages, BMSCs from different passages were 
injected into c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic 
mice to verify plasticity. 
Similar to lal/ mice, hSP-B 1.5-kb lacZ adherent 
BMSCs were able to migrate into the bone marrow, spleen 
and other organs such as the lung (Figure 4B). BMSCs were 
only able to self-renew in the bone marrow and spleen, not 
in the blood and lung as analyzed by the CFSE tracing study 
(Figures 4D and S1). Once being recruited into the lung, 
adherent BMSCs showed the ability to convert into AT II 
epithelial cells by Real-Time PCR, flow cytometry, and 
double immunofluorescence staining (Figure 5). Since this 
conversion did not occur in doxycycline-untreated bitrans-
genic mice, inflammation triggered by Stat3C over-       
expression in myeloid cells is a determining factor for 
BMSC recruitment and conversion. This observation is 
consistent with our previous finding in lal/ mice that ad-
herent subpopulation of bone marrow cells from hSP-B 
1.5-kb lacZ donor mice can convert into AT II epithelial 
cells under the inflammatory and tissue remodeling condi-
tion [7]. While hSP-B 1.5-kb lacZ adherent BMSCs after 9, 
11 and 13 passages from in vitro culturing were able to 
convert into AT II epithelial cells, the same cell population 
after 20 passages lost the ability of conversion in 
c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice. 
To clarify whether systemic inflammation and BMSC 
conversion into AT II epithelial cells are due to malfunction 
of myeloid progenitor cells in the bone marrow, or due to 
the microenvironment change in bitransgenic mice after 
Stat3C over-expression, whole bone marrow transplantation 
was performed to make chimeric mice. After whole bone 
marrow transplantation for three months, recipient wild type 
mice that were received bone marrow cells from 
c-fms-rtTA/(TetO)7-CMV-Stat3C bitransgenic mice devel-
oped systemic inflammation and showed BMSCs-AT II cell 
conversion with doxycycline treatment. In a reverse bone 
marrow transplantation, inflammation and BMSCs-AT II 
cell conversion disappeared in c-fms-rtTA/(TetO)7-CMV-     
Stat3C bitransgenic mice after receiving bone marrow cells 
from wild type mice regardless of doxycycline treatment 
(Figure 6). These results clearly demonstrated that alteration 
of bone marrow progenitor cells, rather than the microenvi-
ronment change, contributes to systematic inflammation and 
BMSCs-AT II cell conversion in c-fms-rtTA/(TetO)7-      
CMV-Stat3C bitransgenic mice. 
As proposed for BMSCs to repair the injured lung [43], 
several conditions must be met: (i) BMSCs must be availa-
ble in the bone marrow; (ii) BMSCs must be mobilized 
from the bone marrow and traffic to the site of injury; (iii) 
BMSCs must be integrated into the existing lung structure, 
divide and differentiate. Based on our observations, these 
events are highly associated with inflammation and myeloid 
cell influx into the lung, suggesting that some common 
mechanisms regulate behaviors of both myeloid cells and 
BMSCs. Since both cells are originated in the bone marrow, 
myeloid cells exert a great impact on BMSC functions. My-
eloid cells synthesize and secret many cytokines and chem-
okines, which not only regulate the myeloid cell behavior 
and function, but also influence BMSCs in a paracrine 
fashion in the bone marrow, circulating system and tissue 
organs. In this report, we demonstrated that Stat3 plays a 
critical role in myeloid cell proliferation and function. As a 
potent transcription factor, Stat3 induces expression of 
many pro-inflammatory cytokines and chemokines in vivo 
as we previously demonstrated [18]. These molecules facili-
tate recruitment of myeloid cells into the damaged organs. It 
is highly possible that the same group of cytokines and 
chemokines mobilizes BMSCs to the damaged site. Identi-
fication of these molecules will greatly benefit regenerative 
medicine and cell-based gene therapy. Since both MDSCs 
and BMSCs suppress T cell proliferation/function to subvert 
immune surveillance and prevent the immune system from 
eliminating tumor cells [34–36,44,45], whether bone mar-
row-derived BMSCs participate in organ pathogenic devel-
opment along with MDSCs in lal/ mice and c-fms-rtTA/    
(TetO)7-CMV-Stat3C bitransgenic mice is an intriguing 
idea and remains to be tested in the future.  
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